

Yu-Li Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3012646/publications.pdf>

Version: 2024-02-01

53
papers

1,325
citations

623734

14
h-index

377865

34
g-index

53
all docs

53
docs citations

53
times ranked

1643
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	10.7	337
2	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	10.7	324
3	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
4	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
5	A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 322.	3.7	32
6	A review of complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. <i>Complementary Therapies in Medicine</i> , 2019, 42, 226-232.	2.7	28
7	Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. <i>Radiology and Oncology</i> , 2014, 48, 314-322.	1.7	27
8	Gender Is a Significant Prognostic Factor for Upper Tract Urothelial Carcinoma: A Large Hospital-Based Cancer Registry Study in an Endemic Area. <i>Frontiers in Oncology</i> , 2019, 9, 157.	2.8	23
9	Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival. <i>Cells</i> , 2020, 9, 806.	4.1	23
10	Proteomics Analysis of Tangeretin-Induced Apoptosis through Mitochondrial Dysfunction in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1017.	4.1	20
11	The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0129268.	2.5	19
12	Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. <i>Scientific Reports</i> , 2018, 8, 7485.	3.3	19
13	Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma. <i>Scientific World Journal</i> , The, 2014, 2014, 1-8.	2.1	15
14	The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e9-495.e14.	1.6	15
15	Asthma and Risk of Prostate Cancer. <i>Medicine (United States)</i> , 2015, 94, e1371.	1.0	14
16	Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. <i>Journal of Cancer</i> , 2016, 7, 1347-1352.	2.5	13
17	Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1653.	4.1	13
18	Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 188.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0169657.	2.5	13
20	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 396-402.	1.1	12
21	Impact of Prognostic Nutritional Index on Overall Survival for Patients with Metastatic Urothelial Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 2466-2471.	2.5	12
22	Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. <i>Frontiers in Oncology</i> , 2020, 10, 584834.	2.8	12
23	Therapeutic outcome of nasopharyngeal carcinoma with cranial nerve palsy: a single institution experience of 104 patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2069-2075.	2.0	11
24	Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 353-360.	1.1	10
25	Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 764912.	2.8	10
26	Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway. <i>Molecules</i> , 2019, 24, 3707.	3.8	9
27	Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3895-3901.	2.0	9
28	Developing a multivariable normal tissue complication probability model to predict late rectal bleeding following intensity-modulated radiation therapy. <i>Journal of Cancer</i> , 2019, 10, 2588-2593.	2.5	8
29	Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment. <i>Cancers</i> , 2021, 13, 5080.	3.7	8
30	Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e21-e22.	1.1	7
31	Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. <i>Journal of Cancer</i> , 2021, 12, 5355-5364.	2.5	7
32	The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 613696.	2.8	6
33	Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8761.	4.1	6
34	Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 114-116.	1.9	5
35	Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma. <i>Oncology</i> , 2020, 98, 146-153.	1.9	5
36	Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. <i>PLoS ONE</i> , 2020, 15, e0229263.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Extracorporeal Shock Wave Enhances the Cisplatin Efficacy by Improving Tissue Infiltration and Cellular Uptake in an Upper Urinary Tract Cancer Animal and Human-Derived Organoid Model. <i>Cancers</i> , 2021, 13, 4558.	3.7	5
38	Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1024.	2.4	4
39	Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. <i>International Journal of Urology</i> , 2016, 23, 385-389.	1.0	3
40	High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. <i>Molecular Medicine Reports</i> , 2017, 16, 7185-7190.	2.4	3
41	Efficacy and safety of uracil-tegafur in patients with recurrent or metastatic thymic carcinoma. <i>Journal of Cancer Research and Practice</i> , 2020, 7, 111.	0.2	2
42	Prognostic Significance of Galectin-1 but Not Galectin-3 in Patients With Lung Adenocarcinoma After Radiation Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 834749.	2.8	2
43	Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2018, 29, ix57.	1.2	1
44	A Narrative Review of Complementary Nutritional Supplements for Chemotherapy-induced Peripheral Neuropathy. <i>Alternative Therapies in Health and Medicine</i> , 2020, 26, 43-49.	0.0	1
45	Left ventricular intracavitary and intramyocardial metastases from renal cell carcinoma. <i>Journal of Echocardiography</i> , 2017, 15, 143-144.	0.8	0
46	Comparison of cisplatin versus carboplatin chemotherapy for metastatic urothelial carcinoma in patients with stage III chronic kidney disease. <i>Annals of Oncology</i> , 2018, 29, ix75.	1.2	0
47	Determine cisplatin or carboplatin in first-line chemotherapy for elderly patients with metastatic urothelial carcinoma: Does age preclude cisplatin eligibility?. <i>Annals of Oncology</i> , 2018, 29, ix76.	1.2	0
48	Oleogranuloma of the Rectum Mimic Malignancy. <i>American Journal of Gastroenterology</i> , 2020, 115, 1747-1747.	0.4	0
49	Confirming Whether KLHL23 Deficiency Potentiates Migration in Urothelial Carcinoma. <i>Chinese Journal of Physiology</i> , 2021, 64, 142-149.	1.0	0
50	276P The survival impact of stromal tumor-infiltrating lymphocytes for patients with metastatic urothelial carcinoma treated with cisplatin-based chemotherapy. <i>Annals of Oncology</i> , 2016, 27, ix86.	1.2	0
51	MP52-15 ANDROGEN DEPRIVATION THERAPY AND SUBSEQUENT HEMATOLOGIC DISORDERS IN 17,168 PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2018, 199, .	0.4	0
52	Panel-derived TMB and immune-related GEP are associated with the response to immune checkpoint inhibitors (ICIs) in urothelial cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17047-e17047.	1.6	0
53	Abstract 3177: Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers. , 2020, , .		0